Ориметен

Ориметен Uses, Dosage, Side Effects, Food Interaction and all others data.

An aromatase inhibitor that produces a state of "medical" adrenalectomy by blocking the production of adrenal steroids. It also blocks the conversion of androgens to estrogens. Ориметен has been used in the treatment of advanced breast and prostate cancer. It was formerly used for its weak anticonvulsant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p454)

Ориметен inhibits the enzymatic conversion of cholesterol to D5-pregnenolone, resulting in a decrease in the production of adrenal glucocorticoids, mineralocorticoids, estrogens, and androgens.

Trade Name Ориметен
Availability Discontinued
Generic Aminoglutethimide
Aminoglutethimide Other Names Aminoglutethimid, Aminoglutéthimide, Aminoglutethimide, Aminoglutethimidum, Aminoglutetimida, Aminoglutetimide, DL-Aminoglutethimide, p-Aminoglutethimide
Related Drugs dexamethasone, estradiol, Premarin, Decadron, cyproheptadine, Arimidex, Xtandi, Ibrance, Femara, Xeloda
Type
Formula C13H16N2O2
Weight Average: 232.2783
Monoisotopic: 232.121177766
Protein binding

21-25%

Groups Approved, Investigational
Therapeutic Class
Manufacturer
Available Country Russia
Last Updated: September 19, 2023 at 7:00 am
Ориметен
Ориметен

Uses

Ориметен is an adrenocortical steroid synthesis inhibitor used in the treatment of Cushing's syndrome.

For the suppression of adrenal function in selected patients with Cushing's syndrome, malignant neoplasm of the female breast, and carcinoma in situ of the breast.

How Ориметен works

Ориметен reduces the production of D5-pregnenolone and blocks several other steps in steroid synthesis, including the C-11, C-18, and C-21 hydroxylations and the hydroxylations required for the aromatization of androgens to estrogens, mediated through the binding of aminoglutethimide to cytochrome P-450 complexes. Specifically, the drug binds to and inhibits aromatase which is essential for the generation of estrogens from androstenedione and testosterone. A decrease in adrenal secretion of cortisol is followed by an increased secretion of pituitary adrenocorticotropic hormone (ACTH), which will overcome the blockade of adrenocortical steroid synthesis by aminoglutethimide. The compensatory increase in ACTH secretion can be suppressed by the simultaneous administration of hydrocortisone. Since aminoglutethimide increases the rate of metabolism of dexamethasone but not that of hydrocortisone, the latter is preferred as the adrenal glucocorticoid replacement. Although aminoglutethimide inhibits the synthesis of thyroxine by the thyroid gland, the compensatory increase in thyroid-stimulating hormone (TSH) is frequently of sufficient magnitude to overcome the inhibition of thyroid synthesis due to aminoglutethimide. In spite of an increase in TSH, aminoglutethimide has not been associated with increased prolactin secretion.

Toxicity

Oral LD50s (mg/kg): rats, 1800; dogs, >100. Intravenous LD50s (mg/kg): rats, 156; dogs, >100. Symptoms of overdose include respiratory depression, hypoventilation, hypotension, hypovolemic shock due to dehydration, somnolence, lethargy, coma, ataxia, dizziness, fatigue, nausea, and vomiting.

Food Interaction

  • Take with or without food. The absorption is unaffected by food.

Ориметен Disease Interaction

Major: adrenal insufficiency

Elimination Route

Rapidly and completely absorbed from gastrointestinal tract. The bioavailability of tablets is equivalent to equal doses given as a solution.

Half Life

12.5 ± 1.6 hours

Elimination Route

After ingestion of a single oral dose, 34%-54% is excreted in the urine as unchanged drug during the first 48 hours, and an additional fraction as the N-acetyl derivative.

Innovators Monograph

You find simplified version here Ориметен

*** Taking medicines without doctor's advice can cause long-term problems.
Share